Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT05318443 Completed - Clinical trials for Non-squamous Non-small-cell Lung Cancer

A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer

Start date: April 17, 2020
Phase: Phase 3
Study type: Interventional

This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer.

NCT ID: NCT05267470 Completed - Clinical trials for Squamous-Cell Non-Small-Cell Lung Cancer

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

FORTITUDE-201
Start date: March 29, 2022
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to evaluate the safety and tolerability of bemarituzumab monotherapy and combination with other anti-cancer therapies, and to determine the recommended phase 3 dose of bemarituzumab in combination with other anti-cancer therapies.

NCT ID: NCT05265897 Completed - Lung Cancer Clinical Trials

Improving Implementation of Lung Cancer Screening in Diverse Populations II

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

This project assesses the feasibility, appropriateness, and acceptability of a "Commonly Asked Questions after Lung Cancer Screening" (CAQ) informational document that the investigators created, resulting from patient and provider discussion in focus groups and interviews. If effective, the CAQ may be a new tool to help improve patient understanding of LCS results and adherence to follow-up recommendations.

NCT ID: NCT05253807 Completed - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

FIGHT-210
Start date: April 29, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options

NCT ID: NCT05226728 Completed - Clinical trials for Non-small Cell Lung Cancer

Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer

Start date: October 10, 2018
Phase: Phase 1
Study type: Interventional

Pembrolizumab with or without chemotherapy has become the standard therapy in advanced non-small cell lung cancer (NSCLC), with a fixed dose of 200mg every 3 weeks. The investigators performed this study to explore the clinical efficacy and safety of pharmacokinetic (PK)-guided pembrolizumab administration in advanced NSCLC.

NCT ID: NCT05213078 Completed - Clinical trials for Stage IV Lung Cancer AJCC v8

Family Caregivers in Underserved Populations Providing Complex Cancer Care

Start date: July 15, 2020
Phase: N/A
Study type: Interventional

This clinical trial develops and tests a model of family caregiver education focused on the role of underserved family caregivers as providers of complex care in the home. Cancer patients have symptoms from their cancer or treatment and are then supported by family caregivers at home with tasks requiring technical skill. Family caregivers are often asked to provide complex care whether it involves decisions about managing symptoms or providing technical care for ports/pumps, tubes, or devices. Family caregivers often are not given enough information on how to provide care for patients at home needing complex care. The results from this study may help researchers refine and improve the intervention for caregivers through future research for caregivers on a much larger scale.

NCT ID: NCT05207423 Completed - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

A Chart Review Study of Adults With Advanced NSCLC

EXTRACT
Start date: October 3, 2022
Phase:
Study type: Observational

The main aim is to see how treatment patterns and drugs might improve care for adults with advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon-20 driven mutations. Past medical records will be reviewed. No clinic visits or procedures will be required.

NCT ID: NCT05205226 Completed - Clinical trials for Non Small Cell Lung Cancer

Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment

Start date: January 2, 2018
Phase:
Study type: Observational

This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.

NCT ID: NCT05167500 Completed - Clinical trials for Metastatic Non Small Cell Lung Cancer

Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

LORLAPULM
Start date: December 9, 2021
Phase:
Study type: Observational

This is an observational, non-interventional, retrospective, multicentre and nationwide study. The information will be obtained retrospectively, in most cases when the treatment has already ended. The primary objective of this study is determine the activity of lorlatinib (percentage of responses, duration of response, progression-free survival and time to treatment failure) of patients included in the compassionate use program in Spain.

NCT ID: NCT05164445 Completed - Lung Cancer Clinical Trials

The Role of Interventional Pulmonology, Microbiota and Immune Response in the Patient With Lung Cancer

RIPMIRLC
Start date: September 1, 2019
Phase: N/A
Study type: Interventional

This study is designed to evaluate complications, specificity, diagnostic yield of radial endobronchial ultrasound guided transbronchial cryobiopsy and transbronchial forceps biopsy with fluoroscopy in the diagnosis of peripheral pulmonary lesion; the interplay between non-small-cell lung cancer associated-bacteria along the gut-lung axis and immune response in the cancer microenvironment.